Targeting protease activated receptor-1 with P1pal-12 limits bleomycin-induced pulmonary fibrosis

Thorax

Volumn 69, Issue 2, 2014, Pages 152-160

  Lin, Cong ^a   Duitman, Jan Willem ^a   Daalhuisen, Joost ^a   Ten Brink, Marieke ^a   Von Der Thüsen, Jan ^b   Van Der Poll, Tom ^a   Borensztajn, Keren ^a,c   Spek, C Arnold ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MEDICAL CENTER HAAGLANDEN   (Netherlands)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BLEOMYCIN; COLLAGEN; FIBRONECTIN; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; P1PAL 12 PEPTIDE; PROTEINASE ACTIVATED RECEPTOR 1; RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; EXTRACELLULAR MATRIX; FIBROBLAST; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING; LOW DRUG DOSE; LUNG FIBROSIS; LUNG LESION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

IDIOPATHIC PULMONARY FIBROSIS; INTERSTITIAL FIBROSIS;

ANIMALS; BLEOMYCIN; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; FIBROBLASTS; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PULMONARY FIBROSIS; RECEPTOR, PAR-1; SIGNAL TRANSDUCTION;

EID: 84892539491     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2013-203877     Document Type: Article

References (35)

1. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378: 1949-61.
2. du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010;9: 129-40.
3. Raghu G, Weycker D, Edelsberg J, etal. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174: 810-6. (Pubitemid 44511663)
4. Ramachandran R. Developing PAR1 antagonists: minding the endothelial gap. Discov Med 2012;13: 425-31.
5. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407: 258-64.
6. Scotton CJ, Krupiczojc MA, Königshoff M, etal. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009;119: 2550-63.
7. Koukos G, Sevigny L, Zhang P, et al. Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury. IUBMB Life 2011;63: 412-18.
8. Ramachandran R, Noorbakhsh F, Defea K, etal. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov 2012; 11: 69-86.
9. Soh UJ, Dores MR, Chen B, etal. Signal transduction by protease-activated receptors. Br J Pharmacol 2010;160: 191-203.
10. Howell DC, Laurent GJ, Chambers RC. Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis. Biochem Soc Trans 2002;30: 211-16.
11. Bogatkevich GS, Tourkina E, Silver RM, etal. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001;276: 45184-92.
12. Tressel SL, Kaneider NC, Kasuda S, etal. A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol Med 2011;3: 370-84.
13. Kaneider NC, Leger AJ, Agarwal A, etal. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007;8: 1303-12. (Pubitemid 350131169)
14. Howell DC, Johns RH, Lasky JA, et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol 2005;166: 1353-65. (Pubitemid 40586507)
15. O'Callaghan K, Kuliopulos A, Covic L. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem 2012;287: 12787-96.
16. Covic L, Misra M, Badar J, et al. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 2002;8: 1161-5. (Pubitemid 35175972)
17. Covic L, Gresser AL, Talavera J, et al. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane tethered peptides. Proc Natl Acad Sci USA 2002;99: 643-8. (Pubitemid 34106565)
18. Zhang G, Kernan KA, Collins SJ, et al. Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. J Am Soc Nephrol 2007;18: 846-59. (Pubitemid 46434501)
19. Yang E, Boire A, Agarwal A, et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt-survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009;69: 6223-31.
20. Cisowski J, O'Callaghan K, Kuliopulos A, et al. Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol 2011;179: 513-23.
21. Borensztajn K, Stiekema J, Nijmeijer S, et al. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am J Pathol 2008;172: 309-20. (Pubitemid 351282019)
22. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41: 467-70. (Pubitemid 18098428)
23. Borensztajn K, Bresser P, van der Loos C, et al. Protease-activated receptor-2 induces myofibroblast differentiation and tissue factor up-regulation during bleomycin-induced lung injury. Am J Pathol 2010;177: 2753-64.
24. Englert JM, Hanford LE, Kaminski N, et al. A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis. Am J Pathol 2008;172: 583-91. (Pubitemid 351354532)
25. Duitman J, Schouten M, Groot AP, et al. CCAAT/enhancer-binding protein 8 facilitates bacterial dissemination during pneumococcal pneumonia in a platelet-activating factor receptor-dependent manner. Proc Natl Acad Sci USA 2012;109: 9113-18.
26. Remillard CV, Yuan JX. PGE2 and PAR-1 in pulmonary fibrosis: a case of biting the hand that feeds you? Am J Physiol Lung Cell Mol Physiol 2005;288; L789-792. (Pubitemid 40547902)
27. Kubo S, Ishiki T, Doe I, et al. Distinct activity of peptide mimetic intracellular ligands (pepducins) for proteinase-activated receptor-1 in multiple cells/tissues. Ann N Y Acad Sci 2006;1091: 445-59. (Pubitemid 47092257)
28. Chambers RC. Role of coagulation cascade proteases in lung repair and fibrosis. Eur Respir J Suppl 2003;44: 33s-5s. (Pubitemid 37222060)
29. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002;3: 349-63. (Pubitemid 34619269)
30. Akhurst RJ, Hata A. Targeting the TGFp signalling pathway in disease. Nat Rev Drug Discov 2012;11: 790-811.
31. Esmon CT. Protein C anticoagulant system - anti-inflammatory effects. Semin Immunopathol 2012;34: 127-32.
32. Degryse AL, Lawson WE. Progress toward improving animal models for idiopathic pulmonary fibrosis. Am J Med Sci 2011;341 444-9.
33. Chambers RC. Gene expression profiling: good housekeeping and a clean message. Thorax 2002;57: 754-6. (Pubitemid 34984970)
34. Goidin D, Mamessier A, Staquet MJ, et al. Ribosomal 18S RNA prevails over glyceraldehyde-3-phosphate dehydrogenase and beta-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations. Anal Biochem 2001;295: 17-21. (Pubitemid 32721736)
35. Bustin SA. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000;25: 169-93.